Cargando…

Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report

Tablets of levothyroxine (LT4) are the most used form for the treatment of hypothyroidism. Some patients may present with refractory hypothyroidism despite a high daily LT4 dose. We report the case of a 49-year-old woman who was admitted to our department for refractory hypothyroidism. She was treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherchir, Faten, Oueslati, Ibtissem, Mouelhi, Yasmine, Talbi, Emna, Feki, Moncef, Yazidi, Meriem, Chihaoui, Melika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623934/
https://www.ncbi.nlm.nih.gov/pubmed/37927364
http://dx.doi.org/10.1177/2050313X231209229
_version_ 1785130837801435136
author Cherchir, Faten
Oueslati, Ibtissem
Mouelhi, Yasmine
Talbi, Emna
Feki, Moncef
Yazidi, Meriem
Chihaoui, Melika
author_facet Cherchir, Faten
Oueslati, Ibtissem
Mouelhi, Yasmine
Talbi, Emna
Feki, Moncef
Yazidi, Meriem
Chihaoui, Melika
author_sort Cherchir, Faten
collection PubMed
description Tablets of levothyroxine (LT4) are the most used form for the treatment of hypothyroidism. Some patients may present with refractory hypothyroidism despite a high daily LT4 dose. We report the case of a 49-year-old woman who was admitted to our department for refractory hypothyroidism. She was treated with 300 μg oral LT4 tablets daily (3.9 μg/kg/day). Despite good compliance and regular intake of high doses of LT4, she had persistent symptoms of hypothyroidism and a thyroid-stimulating hormone level of 92.4 mIU/L. LT4 absorption test was consistent with the diagnosis of malabsorption. Etiological investigations revealed Helicobacter pylori gastritis. Helicobacter infection was adequately treated, but symptoms of hypothyroidism and elevated thyroid-stimulating hormone persisted. Increased LT4 doses (400 μg) failed to normalize thyroid-stimulating hormone levels. Thus, she was put on LT4 liquid form at a dose of 80 drops/day per day (400 µg). Two weeks later, she presented with clinical and biological improvement with a normal free thyroxine level of 1.14 ng/dL. Patients with gastrointestinal disorders may present with refractory hypothyroidism despite increasing doses of LT4. Switching to liquid formulation may resolve this problem.
format Online
Article
Text
id pubmed-10623934
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106239342023-11-04 Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report Cherchir, Faten Oueslati, Ibtissem Mouelhi, Yasmine Talbi, Emna Feki, Moncef Yazidi, Meriem Chihaoui, Melika SAGE Open Med Case Rep Case Report Tablets of levothyroxine (LT4) are the most used form for the treatment of hypothyroidism. Some patients may present with refractory hypothyroidism despite a high daily LT4 dose. We report the case of a 49-year-old woman who was admitted to our department for refractory hypothyroidism. She was treated with 300 μg oral LT4 tablets daily (3.9 μg/kg/day). Despite good compliance and regular intake of high doses of LT4, she had persistent symptoms of hypothyroidism and a thyroid-stimulating hormone level of 92.4 mIU/L. LT4 absorption test was consistent with the diagnosis of malabsorption. Etiological investigations revealed Helicobacter pylori gastritis. Helicobacter infection was adequately treated, but symptoms of hypothyroidism and elevated thyroid-stimulating hormone persisted. Increased LT4 doses (400 μg) failed to normalize thyroid-stimulating hormone levels. Thus, she was put on LT4 liquid form at a dose of 80 drops/day per day (400 µg). Two weeks later, she presented with clinical and biological improvement with a normal free thyroxine level of 1.14 ng/dL. Patients with gastrointestinal disorders may present with refractory hypothyroidism despite increasing doses of LT4. Switching to liquid formulation may resolve this problem. SAGE Publications 2023-11-02 /pmc/articles/PMC10623934/ /pubmed/37927364 http://dx.doi.org/10.1177/2050313X231209229 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Cherchir, Faten
Oueslati, Ibtissem
Mouelhi, Yasmine
Talbi, Emna
Feki, Moncef
Yazidi, Meriem
Chihaoui, Melika
Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title_full Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title_fullStr Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title_full_unstemmed Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title_short Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report
title_sort levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623934/
https://www.ncbi.nlm.nih.gov/pubmed/37927364
http://dx.doi.org/10.1177/2050313X231209229
work_keys_str_mv AT cherchirfaten levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT oueslatiibtissem levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT mouelhiyasmine levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT talbiemna levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT fekimoncef levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT yazidimeriem levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport
AT chihaouimelika levothyroxineliquidoralsubstitutionasanalternativetreatmentforrefractoryhypothyroidismduetogastrointestinalmalabsorptionacasereport